Komori
Qol Holdings (3034) · RiskFirst stated

Impact of the Difference in Reflecting Consumption Tax Rate Revisions in Drug Prices

First written in FY2017. . Latest entry: FY2017.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Earnings impact on the dispensing business from consumption tax rate changes and differences in drug price pass-throughA theme 7 companies write about · 7 as a headwind · 0 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2017First statedAnnual report

    「If the consumption tax rate is revised in the future and the impact is not reflected in drug prices, it could affect our group's performance and other business results.」

    Given the structure in which dispensing revenue is tax-exempt while purchases are taxable, the difference between changes in the consumption tax rate and their reflection in drug prices is identified as a risk.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Qol Holdings's next results are scheduled for 2026-11-05. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Impact of the Difference in Reflecting Consumption Tax Rate Revisions in Drug Prices | Qol Holdings Co.,Ltd. (3034) | Komori